Keywords: Low-Field MRI, Contrast Agent, Low-Field MRI
Motivation: Point-of-care MRI systems have the potential to increase access to imaging. Contrast agents could enhance tissue differentiation at the ultra-low fields of these devices.
Goal(s): To characterize the performance of Gadolinium contrast agents on an FDA cleared, point-of-care MRI system to inform sequence optimization for in vivo imaging.
Approach: Longitudinal relaxivities of six FDA approved gadolinium contrast agents were characterized at 64 mT on a point-of-care MRI device and used to optimize T1 imaging of white matter and CSF.
Results: Longitudinal relaxivities increased at 64 mT compared to their 3 T values. Simulations showed enhancement could be well visualized within feasible sequence parameters.
Impact: Point-of-care MRI systems have the potential to impact patient care by increasing access to imaging. This work explores the feasibility of contrast-enhanced imaging with FDA-approved agents at ultra-low field on a point-of-care MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords